How Does Tagraxofusp (Elzonris) Work Against BPDCN?

Tagraxofusp (brand name Elzonris) is the first FDA-approved targeted therapy specifically designed to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN) ^[1][2]. To understand how it works, it helps to think of the drug as a microscopic “Trojan horse.” It is engineered to seek out and enter cancer cells, though it can also affect healthy cells that share the same target.

The Target: Binding to the CD123 Receptor

BPDCN cells typically have an abundance of a specific protein receptor on their outer surface called CD123 ^[1][3]. A receptor is a receiving molecule on the cell membrane that interacts with substances in the blood. Normal cells—including some healthy immune and blood-forming cells—also carry CD123, but BPDCN cells often express it at very high levels.

Tagraxofusp is a carefully engineered molecule known as a recombinant immunotoxin ^[3][2]. One part of the drug acts as a targeting device—specifically, a protein called interleukin-3 (IL-3) that perfectly matches the shape of the CD123 receptor ^[1][3]. This allows the drug to circulate and bind preferentially to cells expressing CD123 ^[2].

The Trojan Horse: Entering the Cell

Once tagraxofusp locks onto the CD123 receptor, the cell absorbs the drug inside ^[4][2]. This absorption process is the “Trojan horse” effect: the cell pulls the drug through its own outer membrane, bringing the active medication directly into its interior.

The Payload: Disabling Protein Production

Inside the cell, the second part of the drug is released to do its job. This section contains a truncated, engineered fragment of diphtheria toxin ^[1][2]. (This is a noninfectious, laboratory-made component, meaning it cannot give you a diphtheria infection.)

This toxin fragment targets a specific piece of the cell’s machinery called eukaryotic elongation factor 2 (eEF2) ^[4][2]. eEF2 is crucial for building new proteins. The toxin chemically inactivates eEF2, which essentially unplugs the assembly line the cell uses to manufacture the proteins it needs to survive and grow ^[4][1].

Without the ability to make new proteins, the targeted cell’s basic life functions are disrupted, which can lead to cell death ^[4][2]. It is important to note that this cellular process takes time, and your treatment response will be evaluated later using laboratory and bone marrow tests.

Important Safety Information: Capillary Leak Syndrome

Because tagraxofusp can interact with healthy cells that also carry CD123, it is not risk-free. A serious and potentially life-threatening side effect called Capillary Leak Syndrome (CLS) can occur, particularly early in treatment. CLS happens when fluid and proteins leak out of tiny blood vessels into surrounding tissues.

Your care team will monitor you closely, checking your weight, blood pressure, and blood albumin levels before and during treatment. You must contact your care team immediately if you experience warning signs of CLS, such as:

• Sudden or rapid weight gain
• New swelling in your face, arms, or legs
• Dizziness, fainting, or drops in blood pressure
• Shortness of breath
• A noticeable decrease in how often you urinate

Doctors will also check whether your BPDCN cells express CD123 as part of your initial pathology review to help guide your treatment plan. However, expression alone does not guarantee a response, which is why close monitoring of your health and the disease is required throughout therapy.